Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review

Area of Science:

• Neuroscience
• Regenerative Medicine
• Clinical Trials

Background:

• Traumatic spinal cord injury (TSCI) presents significant challenges due to limited central nervous system regeneration.
• Cell therapy, especially using mesenchymal stem cells (MSCs), is a promising avenue for TSCI treatment.

Approach:

• A systematic review analyzed 22 studies (21 clinical trials, 1 case series) from PUBMED and COCHRANE databases up to February 2023.
• Keywords included "spinal cord injury," "stem cells," "mesenchymal stem cells," and "traumatic spinal cord injury".

Key Points:

• MSC-based therapies consistently improved ASIA Impairment Scale grades and sensory scores, with some motor function gains.
• Meta-analyses support the positive outcomes observed in clinical trials.
• Short- and medium-term safety was demonstrated, with no significant adverse events reported within the study timeframe.

Conclusions:

• MSC therapy shows therapeutic potential for TSCI, offering short- to medium-term benefits and safety.
• Limited evidence necessitates caution in generalizing recommendations; long-term safety and efficacy require further investigation.
• Future research should explore gene therapies, neurostimulation, and tissue engineering for comprehensive TSCI treatment strategies.